Tripharma LLC files patent infringement lawsuit for $450 million

Originally posted by Lou Abbott of

Tripharma LLC files patent infringement lawsuit for $450 million

Though I can find no active website for Tripharma or any contact information, Tripharma appears to say this about themselves at

We are a US distributor and marketer of quality nutraceuticals and supplement products including without limitation, the new weight loss product Xellex and the female sexual dysfunction product Xzite.

Xellex was researched and developed at the University of Minnesota where it was awarded Two (2) patents and clinically tested at the University of Connecticut. There is no other product like it for safe, long term effective weight management. It is truly the HOLY GRAIL of over the counter weight loss products and will be available to the general public without a prescription for the first time via US DRTV commercials in May.

Evidently, Tripharma sells a product much like Max International’s MaxWLX product that helps to reset critical leptin sensitivity.  MaxWLX is one of three patented products from Max that include MaxGXL, a glutathione accelerator product, and N-Fuze, a multivitiamin, multimineral product that employs a patented nanotechnology delivery system.

As of the time of this post, a copy of the lawsuit is not yet available.  According to (Recently Filed Cases), it will be available sometime in the next few days.  We will post a copy here as soon as it is available.

I know Max believes they purchased all of the patent rights to this formula and breakthrough.  They have even defended what they perceive to be their rights.  So who is this Tripharma company?  Do they have some kind of valid claim?  It will be interesting to see how this lawsuit develops.

Learn more about Max International here.

1 comment for “Tripharma LLC files patent infringement lawsuit for $450 million

  1. Blackstone
    March 2, 2010 at 12:02 pm

    Imagenetix licensed the right to the patent from University of Minnesota and essentially are co-patent holders at this point.
    Imagenetix then gave exclusive rights to market the formulation to Tripharma.
    Max International did NOT renew their license for 2009, hence the change in the formulation (this information comes first hand from Fred and Greg).
    The first problem is that Max continues to market WLX using the test results of the University of Minnesota’s formulation that the University of Connecticut performed. The current WLX formulation has not had any double-blind controlled tests performed to show its efficacy.

    It is amazing that a 3 year old company has as many lawsuits as Max seems to have.

Leave a Reply

Your email address will not be published. Required fields are marked *